EcoDrugPlus

Amine Oxidase Copper Containing 1

Ensembl ID : ENSCABG00000018650
Gene Symbol: AOC1
1 Cross references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amyloid Beta Precursor Protein

Ensembl ID : ENSCABG00000019841
Gene Symbol: APP
1 Cross references
275 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSCABG00000019592
Gene Symbol: AGTR1
1 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSCABG00000009663
Gene Symbol: AGTR2
1 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Apelin Receptor

Ensembl ID : ENSCABG00000010820
Gene Symbol: APLNR
1 Cross references
172 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSCABG00000010860
Gene Symbol: APH1A
1 Cross references
131 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSCABG00000003967
Gene Symbol: APH1B
1 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSCABG00000008998
Gene Symbol: APEX1
1 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSCABG00000006589
Gene Symbol: ALOX5
1 Cross references
223 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSCABG00000008087
Gene Symbol: ALOX5AP
1 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Arginine Vasopressin Receptor 1b

Ensembl ID : ENSCABG00000003149
Gene Symbol: AVPR1B
1 Cross references
137 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Arginine Vasopressin Receptor 2

Ensembl ID : ENSCABG00000014990
Gene Symbol: AVPR2
1 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).